Related Experiment Video
Updated: Mar 23, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
Namita Chittoria1,2, Housam Haddad3, Paul Elson3
1Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave., Cleveland, OH, USA. namita.chittoria@yahoo.com.
Background:
Axitinib is a potent inhibitor of the vascular endothelial growth factor (VEGF) receptor family with clinical activity in patients with metastatic renal cell carcinoma (mRCC). Given this biochemical potency, the clinical activity of subsequent treatment with targeted therapies in patients progressing on axitinib is of interest.
Methods:
Patients with advanced renal cell carcinoma of any pathologic subtype treated with at least one cycle (four weeks) of axitinib followed by at least one subsequent targeted therapy were investigated in a retrospective analysis. Patient characteristics, duration of treatment and clinical outcomes were analyzed for axitinib and each subsequent line of therapy by Response Evaluation Criteria in Solid Tumors (RECIST).
Results:
Twenty-five mRCC patients who received at least one approved targeted agent following axitinib were identified. Eight percent of patients achieved a partial response (one patient each to sunitinib and pazopanib) and 42 % had a best response of stable disease to the first therapy after axitinib. The estimated median duration of therapy was 4.4 months (range, 0.2-27.5+). Twelve patients received a second post-axitinib targeted therapy. Six out of 11 evaluable patients (55 %) had a best response of SD. The estimated median duration of treatment was 4.8 months (range, 0.7-19.1+).
Conclusion:
Objective responses and stable disease is observed to post-axitinib targeted therapies and prospective studies are needed for validating role of predictive biomarkers.
Insights
Targeted therapies show clinical activity in metastatic renal cell carcinoma (mRCC) patients progressing on axitinib. Objective responses and stable disease were observed, warranting further biomarker research.
Area of Science:
- Oncology
- Medical Research
Background:
- Axitinib effectively inhibits vascular endothelial growth factor (VEGF) receptors, showing clinical activity in metastatic renal cell carcinoma (mRCC).
- Investigating subsequent targeted therapies after axitinib progression is crucial for understanding treatment efficacy.
Purpose of the Study:
- To evaluate the clinical activity of targeted therapies following axitinib treatment in patients with advanced renal cell carcinoma.
- To analyze patient characteristics, treatment duration, and clinical outcomes for axitinib and subsequent therapies.
Main Methods:
- Retrospective analysis of advanced renal cell carcinoma patients receiving axitinib followed by at least one targeted therapy.
- Outcomes assessed using Response Evaluation Criteria in Solid Tumors (RECIST), including response rates and duration of therapy.
Main Results:
- Twenty-five mRCC patients received post-axitinib targeted therapy; 8% achieved partial response and 42% had stable disease on first-line therapy.
- Median duration for first-line post-axitinib therapy was 4.4 months.
- Of 12 patients receiving second-line therapy, 55% had stable disease with a median duration of 4.8 months.
Conclusions:
- Post-axitinib targeted therapies demonstrate objective responses and stable disease in mRCC patients.
- Prospective studies are necessary to validate the role of predictive biomarkers in guiding treatment decisions.
More Related Videos
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention